• Natera will present 35 oncology studies at the American Society of Clinical Oncology Annual Meeting, held May 29-June 2 in Chicago.
• Program includes three oral presentations, with data centered on its Signatera molecular residual disease test across colorectal cancer, lung cancer, lymphoma, breast cancer.
• Key readouts highlighted include a pooled real-world analysis linking Signatera positivity to higher recurrence or death risk in the adjuvant window (HR 8.15) and higher recurrence risk in surveillance (HR 18.3).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.